MedTrace Logo

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

NCT03058757 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2023-01-31

No results posted yet for this study

Summary

The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients

Conditions

Interventions

DRUG

intravesical mitomycin-C 40mg/20ml instillation

neoadjuvant Intravesical mitomycin-C 40mg/20ml instillation * one day before surgery * four hours before surgery

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Ho Kyung Seo, M.D. · National Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2021-02-18
Completion
2022-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058757 on ClinicalTrials.gov